Searched for
WOCKHARDT PHARMA LTD. ET
Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Geopolitical tensions keep markets nervous despite strong earnings: Dipan MehtaGeopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc...
- Sell Wockhardt Pharma with a target of Rs 875: Mitesh ThackerSell Wockhardt Pharma with a target of Rs 875 and a stop loss of Rs 948
- Sell Wockhardt Pharma with a target of Rs 880: Mitesh ThackerSell Wockhardt Pharma with a target of Rs 880 and a stop loss of Rs 966
- Buy Wockhardt Pharma with a target of Rs 1,675: Mitesh Thacker"Wockhardt Pharma Ltd. is a 'BUY' call with a target of Rs 1,675 and a stop loss of Rs 1,594"
- Buy Wockhardt Pharma with a target of Rs 1,500: Mitesh Thacker'Wockhardt Pharma Ltd. is a 'BUY' call with a target of Rs 1,500 and a stop loss of Rs 1,419'
- Prefer Torrent Pharma, Ipca Labs among midcap pharma names: Sudip BandyopadhyayBandyopadhyay is bullish on pharma space. He expects the ongoing weakness in rupee against dollar may help drug makers clock healthy result...
- Buy Wockhardt Pharma with target of Rs 1040: Mitesh Thacker"Wockhardt Pharma is a 'BUY' call with a target of Rs 1040 and a stop loss of Rs 964."
- Buy Wockhardt Pharma with target of Rs 990: Sandeep Wagle"Wockhardt Pharma is a 'BUY' call with a target of Rs 990 and a stop loss of Rs 945."
- Sell Wockhardt Pharma Ltd with target of Rs 188: Sandeep WagleIn a chat with ET Now, Sandeep Wagle, Founder & CEO of Power My Wealth, shares his view on Wockhardt Pharma Ltd.
- Buy Wockhardt Pharma Ltd with a target of Rs 675: Sandeep Wagle"Wockhardt Pharma Ltd is a 'BUY' call with a target of Rs 675 and a stop loss of Rs 602."
- Pharma sector offers many good bets: Kunj BansalMedium- and long-term investors should not be too adventurous with the Wockhardt stock, because the risks seem to be higher.
- Wockhardt story is really intriguing: Deven ChokseyWhere exactly the growth comes from in this particular company is an intriguing question.
- Go for Glenmark Pharma than Ranbaxy or Wockhardt: Jagannadham ThunuguntlaIf somebody is very keen on pharma, we have a better perspective on Glenmark Pharma than Ranbaxy or Wockhardt, he said.
- Expect Wockhardt to cross around Rs 1,200 in next 2-3 years: G Chokkalingam"Wockhardt's management will work hard and they will try to get back the status in two to three years," Chokkalingam said.
- Wockhardt slips over 2% ahead of earningsWockhardt slips over 2% ahead of earningsWockhardt Ltd slipped over 2 percent on Tuesday to touch its day’s low of Rs 680 ahead of its quar...
- Sun flouted foreign currency norms, Wockhardt tells RBIWockhardt has drawn RBIs attention to possible violation of foreign currency laws by Sun Pharma.
- Buy Wockhardt for Rs 362 target: Nimbus Wealth ManagementIt looks a very good buy above Rs 345 for a target of Rs 362 and a stop loss of Rs 338.
- Sun Pharma and Wockhardt not safe bets: Ashish MaheshwariThere will be a slight blow for Wockhardt stock price and this may come down to 200-215 levels.
Load More- Sell Wockhardt Pharma with a target of Rs 875: Mitesh Thacker
